ArticleFrontiers in oncology2025
CCDC58 drives lung adenocarcinoma progression via the PI3K/AKT signaling pathway.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have implicated Coiled-coil domain-containing 58 (CCDC58) in the malignant progression of hepatocellular carcinoma and breast cancer. However, its role in lung adenocarcinoma (LUAD) remains poorly understood. Methods: Bioinformatics analysis was employed to examine CCDC58 expression patterns in LUAD and their correlation with clinical features. We validated CCDC58 expression levels using quantitative real-time PCR (qPCR), Western Blot (WB), and immunohistochemistry staining (IHC). Furthermore, we assessed the impact of CCDC58 knockdown on LUAD cell behavior using proliferation assays, cell migration assays, wound healing assays, and flow cytometry. We explored the effects of CCDC58 knockdown on apoptotic proteins, epithelial-mesenchymal transition (EMT) markers, and PI3K/AKT signaling pathway components through WB. Finally, we evaluated the role of CCDC58 in tumor growth Results: CCDC58 showed significant upregulation in LUAD cell lines and clinical specimens, leading to poor prognosis. CCDC58 expression was identified significant correlation with tumor microenvironment. Conclusions: Above all, this study reveals that CCDC58 plays multiple pro-tumorigenic roles in the progression of LUAD. These results enhance the understanding of LUAD pathogenesis and highlight CCDC58 as a potential therapeutic target and prognostic biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.